17.00
                                            Schlusskurs vom Vortag:
              $16.07
            Offen:
              $16.07
            24-Stunden-Volumen:
                3.01M
            Relative Volume:
              2.36
            Marktkapitalisierung:
                $1.48B
            Einnahmen:
              $12.59M
            Nettoeinkommen (Verlust:
              $-212.39M
            KGV:
              -5.51
            EPS:
                -3.0853
            Netto-Cashflow:
                $-185.92M
            1W Leistung:
              +2.41%
            1M Leistung:
              +37.32%
            6M Leistung:
                +92.09%
            1J Leistung:
              +46.68%
            Immunome Inc Stock (IMNM) Company Profile
Firmenname
                  
                      Immunome Inc
                    
                Sektor
                  Branche
                  Telefon
                  
                      610-321-3700
                    
                Adresse
                  
                      18702 N. CREEK PARKWAY, BOTHELL
                    
                Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                IMNM
                            
                             
                        Immunome Inc 
                           | 
                    17.00 | 1.40B | 12.59M | -212.39M | -185.92M | -3.0853 | 
| 
                         
                          
                                VRTX
                            
                             
                        Vertex Pharmaceuticals Inc 
                           | 
                    426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 | 
| 
                         
                          
                                REGN
                            
                             
                        Regeneron Pharmaceuticals Inc 
                           | 
                    642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 | 
| 
                         
                          
                                ALNY
                            
                             
                        Alnylam Pharmaceuticals Inc 
                           | 
                    434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 | 
| 
                         
                          
                                ARGX
                            
                             
                        Argen X Se Adr 
                           | 
                    826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 | 
| 
                         
                          
                                INSM
                            
                             
                        Insmed Inc 
                           | 
                    186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 | 
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-09-22 | Eingeleitet | Goldman | Buy | 
| 2025-09-05 | Eingeleitet | Craig Hallum | Buy | 
| 2025-04-02 | Eingeleitet | Lake Street | Buy | 
| 2024-11-08 | Eingeleitet | Stephens | Overweight | 
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight | 
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight | 
| 2024-04-15 | Eingeleitet | Guggenheim | Buy | 
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform | 
| 2023-12-19 | Eingeleitet | Wedbush | Outperform | 
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight | 
                    Alle ansehen
                    
                  
                Immunome Inc Aktie (IMNM) Neueste Nachrichten
Immunome (NASDAQ:IMNM) Reaches New 12-Month HighStill a Buy? - MarketBeat
Immunome stock hits 52-week high at 17.34 USD By Investing.com - Investing.com Australia
Immunome stock hits 52-week high at 17.34 USD - Investing.com
Can Immunome Inc. stock deliver surprise earnings beatWeekly Profit Report & Community Driven Trade Alerts - newser.com
Is Immunome Inc. stock a safe haven assetJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Is Immunome Inc. stock bottoming outJuly 2025 Breakouts & High Conviction Trade Alerts - newser.com
Using economic indicators to assess Immunome Inc. potential2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Historical volatility pattern of Immunome Inc. visualized2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com
Chart overlay techniques for tracking Immunome Inc.July 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Can machine learning forecast Immunome Inc. recoveryShort Setup & Accurate Buy Signal Alerts - newser.com
Will Immunome Inc. stock reach Wall Street targets2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - The AI Journal
What technical signals suggest for Immunome Inc. stock2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Immunome Bets Big On Cancer Drugs As Shares Outpace The Market - Finimize
Evaluating Immunome Inc. with trendline analysis2025 Historical Comparison & Weekly Setup with High ROI Potential - newser.com
How Immunome Inc. stock benefits from tech adoptionWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Aug Highlights: How Immunome Inc. stock benefits from tech adoptionMarket Activity Recap & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Immunome (NASDAQ:IMNM) Trading 8.3% HigherTime to Buy? - MarketBeat
Will Immunome Inc. stock outperform Nasdaq indexInsider Selling & Proven Capital Preservation Tips - fcp.pa.gov.br
Can Immunome Inc. stock beat analyst upgradesEarnings Summary Report & Free High Accuracy Swing Entry Alerts - fcp.pa.gov.br
Why Immunome Inc. stock is popular among millennialsLayoff News & AI Driven Stock Price Forecasts - fcp.pa.gov.br
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - TipRanks
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt | 
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director  | 
                        Jun 03 '25  | 
                        Buy  | 
                        9.38  | 
                        5,000  | 
                        46,900  | 
                        36,415  | 
                    
| Higgins Jack | Chief Scientific Officer  | 
                        Mar 27 '25  | 
                        Option Exercise  | 
                        1.35  | 
                        5,200  | 
                        7,020  | 
                        18,729  | 
                    
| BIENAIME JEAN JACQUES | Director  | 
                        Mar 25 '25  | 
                        Buy  | 
                        7.78  | 
                        7,800  | 
                        60,684  | 
                        31,415  | 
                    
| SIEGALL CLAY B | President and CEO  | 
                        Mar 26 '25  | 
                        Buy  | 
                        7.29  | 
                        137,100  | 
                        999,459  | 
                        806,736  | 
                    
| BIENAIME JEAN JACQUES | Director  | 
                        Mar 24 '25  | 
                        Buy  | 
                        8.21  | 
                        7,000  | 
                        57,470  | 
                        23,615  | 
                    
| Tsai Philip | Chief Technology Officer  | 
                        Mar 24 '25  | 
                        Buy  | 
                        8.42  | 
                        12,300  | 
                        103,566  | 
                        33,300  | 
                    
| SIEGALL CLAY B | President and CEO  | 
                        Jan 31 '25  | 
                        Buy  | 
                        7.75  | 
                        150,000  | 
                        1,162,500  | 
                        669,636  | 
                    
| SIEGALL CLAY B | President and CEO  | 
                        Nov 21 '24  | 
                        Buy  | 
                        9.54  | 
                        66,057  | 
                        630,263  | 
                        485,693  | 
                    
| SIEGALL CLAY B | President and CEO  | 
                        Nov 22 '24  | 
                        Buy  | 
                        9.78  | 
                        33,943  | 
                        331,918  | 
                        519,636  | 
                    
| Lechleider Robert | Chief Medical Officer  | 
                        Nov 21 '24  | 
                        Buy  | 
                        9.48  | 
                        15,805  | 
                        149,800  | 
                        15,805  | 
                    
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):